cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cymabay Therapeutics Inc
18 own
34 watching
Current Price
$8.55
$0.02
(0.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
724.02M
52-Week High
52-Week High
8.75
52-Week Low
52-Week Low
1.6701
Average Volume
Average Volume
0.53M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization724.02M
icon52-Week High8.75
icon52-Week Low1.6701
iconAverage Volume0.53M
iconDividend Yield--
iconP/E Ratio--
What does the Cymabay Therapeutics Inc do?
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Read More
How much money does Cymabay Therapeutics Inc make?
News & Events about Cymabay Therapeutics Inc.
Globe Newswire
5days ago
NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously ...
Zolmax
11days ago
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) has been given an average recommendation of Buy by the six analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy ...
Ticker Report
13days ago
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) have been given an average recommendation of Buy by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, two have assigned ...
Globe Newswire
27days ago
Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: ...
Globe Newswire
3 months ago
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients with...
Frequently Asked Questions
Frequently Asked Questions
What is Cymabay Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cymabay Therapeutics Inc shares?
plus_minus_icon
How can I buy Cymabay Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cymabay Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cymabay Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cymabay Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cymabay Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cymabay Therapeutics Inc?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$8.55
$0.02
(0.23%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00